United States Humanized Mice Model Market By Type (Genetic Humanized Mice Model, Cell-based Humanized Mice Model), By Application (Oncology Studies, Immunology and Inflammation Studies, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations), By Region, Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 38.53 Million
CAGR (2026-2031)	6.12%
Fastest Growing Segment	Genetic Humanized Mice Model
Largest Market	North-East
Market Size (2031)	USD 55.03 Million

Market Overview

The United States Humanized Mice Model Market will grow from USD 38.53 Million in 2025 to USD 55.03 Million by 2031 at a 6.12% CAGR. The United States Humanized Mice Model Market involves the development, production, and utilization of genetically modified or engrafted immunodeficient mice with functional human cells, tissues, or genes. These models are designed to closely mimic human biological systems, making them invaluable tools for research into complex human diseases and the preclinical evaluation of novel therapeutic agents. Key drivers supporting this market's expansion include the increasing focus on developing human-relevant in vivo models to improve drug discovery success rates and the growing need for sophisticated platforms to study intricate conditions such as immuno-oncology, infectious diseases, and autoimmune disorders. The rising expenditure on pharmaceutical and biotechnology research and development further stimulates demand for these specialized models.

However, a significant challenge impeding market expansion is the inherent complexity and high cost associated with the development, maintenance, and ethical oversight of these advanced animal models. Despite these challenges, the Federation of American Societies for Experimental Biology (FASEB), an industrial association, reaffirmed in December 2025 the essential and ongoing role of non-human animals in advancing biomedical discovery, acknowledging that computational and in vitro approaches often cannot yet replace whole-animal research, thereby underscoring the sustained importance of animal models, including humanized mice, in critical research pathways.

Key Market Drivers

R&D Expansion in Pharma and Biotech Drives US Preclinical Model Demand
The expanding pharmaceutical and biotechnology research and development landscape significantly influences the United States Humanized Mice Model Market by increasing the need for advanced preclinical testing platforms. As drug developers pursue novel therapies for complex diseases, the demand for in vivo models that accurately replicate human biology intensifies for evaluating drug efficacy, toxicity, and pharmacokinetics. According to BioSpace, in March 2026, in the 'Pharma R&D Spend Drops 3.6% as Pipeline Prioritizations Take Shape' article, the top 16 largest pharmaceutical companies collectively spent $159 billion on research and development in 2025, underscoring the substantial investment driving the need for sophisticated preclinical tools that offer a more predictive platform for drug evaluation.

Growth of Personalized Medicine Fuels Demand for Humanized Mice Models
The growth in personalized medicine initiatives also acts as a pivotal driver for the United States Humanized Mice Model Market. Personalized medicine requires preclinical models capable of mimicking individual patient responses or specific genetic profiles to test targeted therapies, a capability humanized mice provide through engineered human immune systems or tissue engraftments. These specialized models enable researchers to study disease progression and therapeutic responses in a human-relevant context. According to Top Doctor Magazine, in March 2026, in the 'Precision Medicine Personalized Treatment Plans (2026)' article, the global cell and gene therapy market is projected to grow from $25 billion in 2025, highlighting the increasing focus on individualized treatments that benefit from humanized mouse models. This trend, coupled with overall U.S. prescription drug spending surging 12.7% to $915 billion in 2025, according to ASHP in April 2026, reinforces continuous demand for advanced preclinical tools supporting diverse new medications.

Download Free Sample Report

Key Market Challenges

Costs and Complexity Limit Adoption of Humanized Mice
The primary impediment to the expansion of the United States Humanized Mice Model Market stems from the significant complexity and elevated costs associated with the development, ongoing maintenance, and stringent ethical oversight of these specialized animal models. These factors directly translate into higher operational expenses for research institutions and pharmaceutical companies, thereby limiting the accessibility and widespread adoption of humanized mice. The intricate procedures involved in genetic modification or engraftment, coupled with the necessity for highly controlled environments and specialized personnel, contribute substantially to the overall expenditure required to utilize these advanced research tools.

Funding Constraints and Overhead Caps Impede Market Growth
This substantial financial burden can constrain the number of studies utilizing humanized mice, particularly for smaller biotechnology firms or academic laboratories with restricted budgets. Consequently, while the research utility of humanized mice is well-recognized, the significant investment required acts as a deterrent, potentially slowing the pace of drug discovery and development reliant on these platforms. According to the Federation of American Societies for Experimental Biology (FASEB), in August 2025, efforts to cap Facilities and Administrative costs at 15 percent across federal science agencies underscore the ongoing challenge of adequately funding the comprehensive operational overhead associated with complex animal research, which includes specialized model maintenance and ethical compliance. This limitation on cost recovery directly hinders the capacity of institutions to absorb the inherent high costs of humanized mouse models, thereby impeding market growth.

Key Market Trends

CRISPR-Driven Precision in Humanized Mouse Models
Advanced Gene Editing for Model Precision represents a significant trend in the United States Humanized Mice Model Market, focusing on enhancing the accuracy and human relevance of research models. This trend involves leveraging technologies like CRISPR-Cas9 to introduce specific human genetic alterations, thereby creating models that more faithfully mimic human disease pathologies and therapeutic responses. The ability to precisely modify genetic sequences in humanized mice allows for the development of highly specific models essential for targeted drug discovery and validation. According to Cure, in March 2026, CRISPR Therapeutics announced it would raise an upsized $550 million through a convertible senior notes offering, reflecting sustained investment in advanced gene-editing capabilities that underpin the development of these refined models.

Demand for Organ-Specific, Physiologically Relevant Models
Another influential trend is the Increased Demand for Physiologically Relevant Organ-Specific Models. This trend emphasizes the need for humanized mouse models that not only incorporate human cells or tissues but also accurately replicate the complex physiological functions and disease manifestations within specific human organ systems. Such models are crucial for a deeper understanding of organ-specific diseases and for evaluating therapies with minimal translational gaps to human clinical trials. For example, research into complex conditions like oncology drives the need for models that can accurately represent tumor microenvironments and immune interactions. According to BioSpace, in March 2026, oncology applications are expected to constitute a dominant share of 35.2% within the humanized mouse model market, demonstrating the substantial demand for precise and physiologically representative models in this critical therapeutic area.

Segmental Insights

Rapid Growth Fueled by Precision and Personalized Medicine
The Genetic Humanized Mice Model segment stands out as the fastest-growing within the United States Humanized Mice Model Market, primarily due to its exceptional precision in replicating human gene function and intricate immunological pathways. This growth is significantly driven by the escalating demand for personalized medicine and targeted therapies, allowing researchers to accurately investigate human-specific gene function and molecular interactions. The increasing adoption of these models in critical research areas like oncology and immunology, supported by institutions such as the U.S. National Institutes of Health, further accelerates their expansion by reducing the translational gap in preclinical studies.

Regional Insights

North-East: Market Leader Fueled by Research Ecosystem and Investment
The North-East region stands as the leading segment in the United States Humanized Mice Model Market, driven by its high concentration of world-class research institutions and prominent biotechnology and pharmaceutical companies. This dominance is attributed to a robust funding landscape, including significant government support and venture capital investments that fuel extensive research and development activities. Key biotechnology hubs like Boston/Cambridge and the New York/New Jersey corridor provide advanced infrastructure and expertise for preclinical studies, accelerating innovations in drug discovery and personalized medicine, and supporting a strong supplier presence within the region.

Recent Developments

• In October 2025, The Jackson Laboratory announced a strategic alliance with The New York Stem Cell Foundation. This collaboration aims to integrate stem cells, advanced mouse models, data analysis, and machine learning into a unified discovery platform. The initiative is designed to accelerate biomedical research, including the development of new therapies for various diseases. By combining The Jackson Laboratory's expertise in mouse models, which includes humanized mice, with The New York Stem Cell Foundation's stem cell science, the partnership is set to offer more robust platforms to researchers, significantly impacting the United States humanized mice model market by enhancing research capabilities.
• In October 2025, GemPharmatech announced a research collaboration with Memorial Sloan Kettering Cancer Center. This agreement provides researchers at Memorial Sloan Kettering with access to GemPharmatech's preclinical service capabilities and resources, particularly its NeoMab® platform. The NeoMab® platform utilizes an immunoglobulin gene-humanized mouse model for the rapid and efficient discovery of fully human therapeutic antibodies against cancer targets. This collaboration underscores GemPharmatech's commitment to advancing therapeutic antibody discovery, directly contributing to the innovation within the United States humanized mice model market by providing specialized models for oncology research.
• In October 2025, Crown Bioscience presented breakthrough research on humanized engineered syngeneic mouse models at SITC 2025. This study showcased the application of these models for evaluating the synergy between antibody-drug conjugates and immune checkpoint inhibitors. The models, which maintain an intact immune system, provide a physiologically relevant environment to study therapeutic synergy and immune modulation. This research, utilizing humanized genetically modified mouse models, is crucial for advancing the preclinical assessment of combination therapies, thereby driving innovation and offering more predictive platforms within the United States humanized mice model market.
• In 2024, Taconic Biosciences received a Novel Product Award at the Merck Technology Symposium for its FcResolv® NOG portfolio. This recognition highlighted the portfolio's significant applications in advancing preclinical antibody-based drug discovery. The FcResolv® NOG models are a type of super immunodeficient mouse specifically engineered to lack murine Fc gamma receptors. This modification improves the accuracy of results when assessing antibody-based therapeutics, directly impacting the development of novel immunotherapies within the United States humanized mice model market by providing more relevant preclinical data.

Key Market Players

• Charles River Laboratories International, Inc.
• The Jackson Laboratory
• Taconic Biosciences Inc.
• Hera BioLabs
• Ingenious Targeting Laboratory Inc.
• Champions Oncology, Inc.
• Yecuris Corporation
• Crown Bioscience Inc.
• Taconic Biosciences Inc.
• HuMurine Technologies

By Type	By Application	By End User	By Region
Genetic Humanized Mice Model Cell-based Humanized Mice Model	Oncology Studies Immunology and Inflammation Studies Others	Pharmaceutical & Biotechnology Companies Academic & Research Institutes Contract Research Organizations	Northeast Midwest South West

Report Scope:

In this report, the United States Humanized Mice Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Humanized Mice Model Market, By Type:

• Genetic Humanized Mice Model
• Cell-based Humanized Mice Model

• United States Humanized Mice Model Market, By Application:

• Oncology Studies
• Immunology and Inflammation Studies
• Others

• United States Humanized Mice Model Market, By End User:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations

• United States Humanized Mice Model Market, By Region:

• Northeast
• Midwest
• South
• West